News Focus
News Focus
icon url

DewDiligence

04/21/14 9:40 PM

#177098 RE: dewophile #177092

ENTA—PIs have had a history of toxicity so why not get them both in the clinic.

I expect ABT-493 will supersede ABT-450 before ABBV starts a pivotal trial in GT3, provided that the ABT-493 + ABT-530 combination reveals no problems.